Comunidado Ionis
Ionis anuncia resultados preliminares positivos del ensayo de fase 1/2a de ION582 para el síndrome de Angelman 16 de mayo de 2024 a las 7:00 a. m. EDT ION58
Ionis anuncia resultados preliminares positivos del ensayo de fase 1/2a de ION582 para el síndrome de Angelman 16 de mayo de 2024 a las 7:00 a. m. EDT ION58
Solo faltan 2 días para que los amantes del flamenco podamos disfrutar de un concierto solidario en el que el Síndrome de Angelman será protagonista. Todo
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (
Watch all the news and updates from the Science Summit 9-5pm Friday, December 2 (CST) and
the Education Summit on Saturday December 3, 9-4PM.
written by Allyson Berent, DVM DACVIM When we refer to gene therapy in Angelman Syndrome (AS), we are typically referring to a “viral delivery” or “vir
Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model
Dr Allyson Berent, the Chief Science Officer at the Foundation for Angelman Syndrome Therapeutics, talks with popular radio journalist Maggie Linton about An
Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome
Read our regular series summarizing lectures presented on Friday December 4th, 2015, the first day of the 2015 FAST Global Summit. This series will be focuse
Watch all the presentations from the 2015 Science Summit in Chicago